Kern U., Martin C., Scheicher S., Müller H. (2003) Treatment of phantom pain with botulinum-toxin A. A pilot study Schmerz 17, 117-124
Kern U., Martin C., Scheicher S., Müller H. (2004) Long-term treatment of phantom- and stump pain with Botulinum toxin type A over 12 months. A first clinical observation Nervenarzt 75, 336-340
Kern U., Martin C., Scheicher S., Müller H. (2006) Referred pain from amputation stump trigger points into the phantom limb. Schmerz 20, 300, 302-306
Kern U., Busch V., Rockland M., Kohl M., Birklein F. (2009) Prevalence and risk factors of phantom limb pain and phantom limb sensations in Germany. A nationwide field survey Schmerz 23, 479-488
Kern U., Kohl M., Kiefer R.-T. (2010) Lidocaine patch for therapy of neuropathic and non-neuropathic pain: A clinical case series of 87 patients. Nervenarzt 81, 1490-1497
Kern U., Altkemper B., Kohl M. (2006) Management of phantom pain with a textile, electromagnetically-acting stump liner: a randomized, double-blind, crossover study J Pain Symptom Manage 32, 352-360
Kern U., Kohl M., Seifert U., Schlereth T. (2011) Botulinum toxin type B in the treatment of residual limb hyperhidrosis for lower limb amputees: a pilot study. Am J Phys Med Rehabil 90, 321-329
Kern U., Martin C., Scheicher S., Müller H. (2003) Botulinum toxin type A influences stump pain after limb amputations. J Pain Symptom Manage 26, 1069-1070
Kern U., Martin C., Scheicher S., Müller H. (2004) Effects of botulinum toxin type B on stump pain and involuntary movements of the stump. Am J Phys Med Rehabil 83, 396-399
Kern U. (2004) Influence of botulinum toxin on postamputation pain and phantom limbs. J Neurol Feb 251 Suppl 1, I/42
Kern U., Martin C., Scheicher S., Müller H. (2004) Does botulinum toxin A make prosthesis use easier for amputees? J Rehabil Med 36, 238-239
Koch H., Kern U., Busch V. (2009) Therapeutische Wirkung von Ausdauersport bei Migräne: Explorative Metaanalyse sportmedizinischer Studien. MMW-Forschritte der Medizin Originalien Nr.II, 59-62
Reilich P., Fheodoroff K., Kern U., Mense S., Seddigh S., Wissel J., et al. (2004) Consensus statement: botulinum toxin in myofascial pain. J Neurol 251 Suppl 1, I36-38
England J., Wagner T., Kern U., Roth-Daniek A., Sell A. (2011) The capsaicin 8% patch for peripheral neuropathic pain: practical guidance, hints and tips on the application process. Br J Nurs. 2011 Aug 11-Sep 8;20(15):926-31
Kern U., Kohl M., Seifert U., Schlereth T. (2012) Botulinumtoxin Typ B lindert Stumpfschmerzen und Stumpfschwitzen - Chance zur indirekten Phantomschmerz-Reduktion durch bessere Prothesen-Nutzung? Schmerz. 2012 Apr;26(2):176-84
Kern U., Busch V., Mueller R., Kohl M., Birklein F. (2012) Phantom limb pain in daily pratice - still a lot of work to do! Pain Med. 2012 Sep 26. doi:10.1111/j.1526-4637.2012.01494.x
Mick G., Baron R., Kern U., Hans G., Finnerup N. B., Dworkin R. H. (2011) Localized neuropathic pain: clinical characteristics and a proposed definition. Pain Manage. (2012) 2(1), 71–77
Wagner T., Roth-Daniek A., Sell A., England J., Kern U. (2012) The capsaicin 8% patch for peripheral neuropathic pain: Review of treatment best practice from 'real world' clinical experience. Pain Manage 2012;2: 239-250
Kern U., Nolte T. (2008) 25 years of progress in pain therapy: the rocky road to recognition. MMW Fortschr Med 150, 115-117
Kiefer T.-R., Kern U., Bredanger S. (2008) Chronische Knieschmerzen: ein außergewöhnlicher Fall. Angewandte Schmerztherapie 2, 45-48
Kern U. (2006) Botulinumtoxin beim myofaszialen Schmerzsyndrom. Schmerztherapie Nr.1 18-19
Kern U., in Fayyaz A., Jost W.-H. (ed.) (2003) BTX - A in the treatment of Phantom Pain. Wissenschaftsverlag Wellingsbüttel Hamburg
Kern U., in Junker U., Nolte T. (ed.) (2005) Grundlagen der speziellen Schmerztherapie. Verlag Medizin & Wissen, München
Kern U., in Ningel R., Funke W. (ed.) (1995) Soziale Netzwerke in der Praxis. Verlag für angewandte Psychologie, Göttingen
Busch V., Magerl W., Kern U., Haas J., Hajak G., Eichhammer P. (2012) The effect of deep and slow breathing on pain perception, autonomic activity and mood processing. An experimental study Pain Med. 2012 Feb;13(2):215-28
Kern U., England J., Roth-Daniek A., Wagner T. Is physician supervision of the capsaicin 8% patch administration procedure really necessary? An opinion from health care professionals J Pain Res. 2013 Jul 19;6:571-5
Kern U., Nalamachu S., Brasseur L., Zakrzewska J.-M. Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain? J Pain Res. 2013 Apr 5;6:261-80
Kern U., Bialas P., Fangmann D. Prolonged-release tapentadol for phantom pain. A case series Schmerz. 2013 Apr 27;(2):174-81
Treede R.-D., Wagner T., Kern U., Husstedt I.-W., Arendt G., Birklein F., Cegla T., Freynhagen R., Gockel H.-H., Heskamp M.-L., Jager H., Joppich R., Maier C., Leffler A., Nagelein H.-H., Rolke R., Seddigh S., Sommer C., Stander S., Wasner G., Baron R. Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain. Curr Med Res Opin. 2013 May 29&;(5):527-38
Baron R., Kern U., Müller M., Dubois C., Falke D., Steigerwald I. Effectiveness and olerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study. Pain Pract. 2014 Apr 18
Kern U., Nowack W., Poole C. Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary? Pain Pract. 2014 Feb 14;(2):E42-50
Baron R, Kern U, Muller M et al. (2015) Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study. Pain practice : the official journal of World Institute of Pain 15:471-486
Kern KU, Baust H, Hofmann W et al. (2014) Capsaicin 8 % cutaneous patches for phantom limb pain. Results from everyday practice (non-interventional study). Schmerz 28:374-383
Kern KU, Bialas P, Fangmann D (2013) Prolonged-release tapentadol for phantom pain. A case series. Schmerz 27:174-181
Kern KU, England J, Roth-Daniek A et al. (2013) Is physician supervision of the capsaicin 8% patch administration procedure really necessary? An opinion from health care professionals. Journal of pain research 6:571-575
Kern KU, Krings D, Waldmann-Rex S (2014) Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone. MMW Fortschritte der Medizin 156 Suppl 2:54-63
Kern KU, Nalamachu S, Brasseur L et al. (2013) Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain? Journal of pain research 6:261-280
Kern KU, Nowack W, Poole C (2014) Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary? Pain practice : the official journal of World Institute of Pain 14:E42-50
Sanchez Del Aguila MJ, Schenk M, Kern KU et al. (2015) Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. Clinical therapeutics 37:94-113
Schlereth T, Heiland A, Breimhorst M et al. (2015) Association between pain, central sensitization and anxiety in postherpetic neuralgia. European journal of pain 19:193-201
Treede RD, Wagner T, Kern KU et al. (2013) Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain. Current medical research and opinion 29:527-538
Kern KU, Weiser T. (Dec. 2015) Topical ambroxol for the treatment of neuropathic pain : A first clinical observation. German version Schmerz, 29(6):632-40 doi:10.1007/s00482-015-0065-6 (online verfügbar)
Kern KU, Weiser T. (dec. 2015) Topical ambroxol for the treatment of neuropathic pain : An initial clinical observation. English version Schmerz, 29(Suppl 3):89-96 (online verfügbar)
Kern U (2013) Komponenten der Analgesie durch Akupunktur spezifiziert (Kommentar). JC Schmerzmed 2:213
Kern U (2014) Die Faktoren für chronische Schmerzen nach Brustkrebs-OP (Kommentar). JC Schmerzmed 3:76-76
Kern U (2015) Medikamentöse Kombinationstherapie bei Polyneuropathie (Kommentar). JC Schmerzmed 4:157-157
Kern U (2015) Schmerzlinderung durch Berührung: Mechanismen genauer entschlüsselt (Kommentar). JC Schmerzmed 3:83
Kern U (2016) Pharmakotherapie neuropathischer Schmerzen; Topische Therapien ergänzen bewährte systemische Konzepte. Deutsche Apothekerzeitung 156:46-52
Kern U (2016) Neuraltherapeutische Injektionstechniken bei Rückenschmerz (Kommentar). JC Schmerzmed 5:129-129
Baron R, Eberhart L, Kern KU et al. (2016) Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data. Pain practice : the official journal of World Institute of Pain
Kern U (2016) Lokaltherapie mit Lidocain u. therapeutische Lokalanästhesie (Kap. 5); Lokaltherapie mit speziellen Substanzen (Kap. 7). In: Moderne Praxis der analgetischen Lokaltherapie, UNI-MED Science, 1. Aufl. (Editor C. Maihöfner)
Lintzeris N, Bhaskar A, Kraus M et al. (2017) Consensus and controversies between pain and addiction experts on the prevention, diagnosis and management of opioid analgesic dependence. JAMA submitted
Kern KU, Schwickert-Nieswandt M, Maihöfner C, Gaul C (2019) Topical Ambroxol 20% for the Treatment of Classical Trigeminal Neuralgia - A New Option? Initial Clinical Case Observations. Headache. 2019 Mar;59(3):418-429
Maihöfner C, Schneider S, Bialas P, Gockel H, Beer KG, Bartels M, Kern KU (2018) Successful treatment of complex regional pain syndrome with topical ambroxol: a case series. Pain Manag. 2018 Nov 1;8(6):427-436
Poehlke T, Gralow I, Kern U et al. (2017) Empfehlungen zur Substitutionstherapie mit Buprenorphin/Naloxon bei behandlungsbedürftiger Medikamentenabhängigkeit von Opioiden. Sonderveröffentlichung
Baron R, Treede RD, Birklein F et al. (2017) Treatment of painful radiculopathies with capsaicin 8% cutaneous patch. Current medical research and opinion:1-25
Kern U, Krings D, Waldmann-Rex S (2017) Tapentadol Prolonged Release Improves Analgesia, Functional Impairment and Quality of Life in Patients with Chronic Pain who have Previously Received Oxycodone/Naloxone. J Pain Relief 6:281. doi 10.4172/2167-0846.1000281
Kern KU, Schwickert M (2017) Ambroxol for the treatment of fibromyalgia: science or fiction? Journal of pain research 10:1905-1929
Kern KU, Schwickert-Nieswandt M (2019) Postherpetic neuralgia of the left trigeminus nerve V1: Successful therapy with capsaicin 8% patch. Schmerz 2018 Dec;32(6):464-467
Kern KU (2019) Update Orthopädie Hot Topic: Schmerz. Orthopade 2019 Apr;48(4):348-349
Kern KU, Sohns M, Heckes B, Elling C. (2020) Tapentadol prolonged release for severe chronic osteoarthritis pain in the elderly: improvements in daily functioning and quality of life. Pain Manag. 2020 Mar;10(2):85-95
Kraus M, Lintzeris N, Bhaskar A, Alho H, Alon E, Bouhassira D, Haro G, D'Agnone O, Dematteis M, Kern KU, Maremmani I, Perrot S, Sittl R, Pellicano K. (2020) Consensus and Controversies Between Pain and Addiction Experts on the Prevention, Diagnosis, and Management of Prescription Opioid Use Disorder. J Addict Med. 2020 Jan/Feb;14(1):1-11
Huygen F, Kern KU, Pérez C. Expert Opinion: Exploring the Effectiveness and Tolerability of Capsaicin 179 mg Cutaneous Patch and Pregabalin in the Treatment of Peripheral Neuropathic Pain. J Pain Res. 2020 Oct 14;13:2585-2597
Schubert T., Kern K.-U., Schneider S., Baron R. Oral or Topical Pain Therapy - How Would Patients Decide? A Discrete Choice Experiment in Patients with Peripheral Neuropathic Pain. Pain Pract. 2021 Jun;21(5):536-546
Swidan S (Herausgeber), Bennett M (Herausgeber), Kern KU (Chapter author 'Fibromyalgia') Advanced Therapeutics in Pain Medicine Taschenbuch - CRC Press; 1. Edition (2020 Dec 20)
Kern U. Hochdosiertes Capsaicin-Pflaster in der Behandlung peripherer neuropathischer Schmerzen. Ein Erfahrungsbericht mit 58 Patienten. Psychopharmakotherapie, 2012. 19: p. 72-5
Kern K.-U., Vogelmann T., Tölle T. R. Tapentadol versus klassische WHO-III-Opioide bei chronischen Rückenschmerzen Versorgungsforschungsstudie auf Basis repräsentativer Krankenkassendaten MMW-Fortschritte der Medizin 2022; 164 (S6): 19–27
Russo M.-A., Baron R., Dickenson A.-H., Kern K.-U., Santarelli D.-M. Ambroxol for neuropathic pain: hiding in plain sight? Pain. 2023 Jan 1;164(1):3-13
Kern K.-U. Low back pain management in routine clinical practice: what is important for the individual patient? Pain Manag. 2023 Apr;13(4):243-252
Kern K.-U., Quandel T., Theis S., Schubert T. Characteristics and outcomes of peripheral neuropathic pain patients with repeated applications of high-concentration capsaicin cutaneous patch: Results of a retrospective chart review in Germany. Pain Pract. 2024;00:1–9.
